Project Grant R01HL172872
Award Date
4/4/25
Completion Date
1/31/29
Dollars Obligated
$828K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $880,735 project grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Washington from Feb 1, 2025 to Nov 30, 2028. The grant supports research to investigate the mechanisms by which loss of plasma membrane integrity triggers the release of interleukin-33 and leukotriene C4, thereby activating group 2 innate lymphoid cells and initiating type 2 immune responses in the lung. The research aims to elucidate how...
This $186,408 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to evaluate the potential of targeting the CD14 protein as a novel therapeutic approach for treating acute respiratory distress syndrome (ARDS). The primary objectives are to: 1) analyze gene expression data to determine the effects of the CD14-blocking monoclonal antibody IC14 on cellular targets, 2) assess the...
This $730,876 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) will support research to determine how alveolar macrophage (AM) subset ontogeny and function contribute to clinical outcomes in acute respiratory distress syndrome (ARDS). The primary objectives are to leverage AM chimerism in lung transplant recipients to test if recruited blood monocytes can mature into either protective...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is providing a $737,815 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis. The grant, awarded on January 28, 2025, supports the development and validation of an automated electronic health record (EHR)-embedded Clinical Classifier Model (CCM) system to rapidly identify molecular phenotypes of acute respiratory distress...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996.00 to the University of Southern California to study the role of the protein PDLIM2 in regulating alveolar macrophage function and its impact on lung cancer, lung diseases, and pneumonia. The project aims to determine the mechanisms by which PDLIM2 modulates alveolar macrophage phagocytosis, immune response, and...
The University of Washington was awarded a $466,500 Project Grant (R21HL172011) from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to develop a novel diagnostic pipeline that leverages computer vision and computational fluid dynamics to accurately quantify airway anatomy and respiratory effort in pediatric patients with subglottic stenosis. The goal is to improve diagnosis and treatment planning for this sensitive population by providing a more...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $739,362 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University in St. Louis. The 4-year grant, with an award date of Aug 26, 2024, supports research to explore how a genetic variant in the Coenzyme Q6 (COQ6) gene impacts inflammatory responses and organ damage during pneumococcal sepsis. The research aims to challenge the conventional immune-centric model of sepsis by...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $163,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Ann & Robert H Lurie Children's Hospital of Chicago. The grant, which runs from September 1, 2024 to August 31, 2029, will fund research to understand the age-specific mechanisms that promote recovery from severe viral pneumonia in children. Specifically, the project will examine whether juvenile regulatory T cells have impaired...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $480,990 to the University of Illinois to conduct research on the role of aerocytes, a specialized capillary endothelial cell population, in facilitating alveolar epithelial regeneration following lung injury associated with conditions like acute respiratory distress syndrome (ARDS). The research aims to establish the central regulatory...
This $644,365 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The primary objective is to identify novel strategies to mitigate cardiac damage and dysfunction following invasive pneumococcal disease, which is a major driver of adverse cardiac events and cardiovascular mortality in community-acquired pneumonia patients. The award supports research at the University of Alabama at...